SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3

Kenji Nakahama, Masahiko Osawa, Motohiro Izumi, Naoki Yoshimoto, Akira Sugimoto, Hiroaki Nagamine, Koichi Ogawa, Yoshiya Matsumoto, Kenji Sawa, Yoko Tani, Hiroyasu Kaneda, Shigeki Mitsuoka, Tetsuya Watanabe, Kazuhisa Asai, Tomoya Kawaguchi